Clifford Chance advises UCB on the acquisition of IMIDomics’ Patient Insight Business

28 May 2026

• Patrice Viaene, Katharine Missenden, Carme Briera Dalmau, Jorge Martín-Fernández, Adrián Crespo Velasco, Fernando Escribano, , Sébastien Nerincx, Olga Albalá, Ainhoa Cendon Rey,
• Brussels, Barcelona, Madrid

Clifford Chance advises UCB on the acquisition of IMIDomics’ Patient Insight Business

Global law firm Clifford Chance has advised UCB, a global biopharmaceutical company focused on immunology and neurology, on its acquisition of IMIDomics’ Patient Insight Business.

The acquisition represents an important step for UCB in strengthening its capabilities in immune-mediated inflammatory diseases by providing access to a highly curated patient data platform, including clinical information, biological samples and multi-omics datasets, built over many years through a global clinical network. It supports UCB’s strategy to advance precision medicine and enhance its research and development capabilities.

IMIDomics, a biotechnology company focused on immune-mediated inflammatory diseases, has developed this patient insight platform over many years through a global clinical network, supported by the Vall d’Hebron Institute of Research (VHIR) in Barcelona.

The cross-border Clifford Chance team was led by Patrice Viaene (Partner, Brussels) and José Maria Vilaseca (Senior Associate, Barcelona), and further comprised Katharine Missenden (Counsel, Brussels), Sébastien Nerincx (Associate, Brussels), Carme Briera (European Senior Counsel, Barcelona), Jorge Martín-Fernández (Counsel, Madrid), Olga Albalá (Associate, Madrid), Fernando Irurzun (Partner, Madrid); Ainhoa Rey (Associate, Barcelona); Adrián Crespo (Counsel, Barcelona); Fernando Escribano (Counsel, Madrid); Estel Casas (Associate, Barcelona).  

Press contact: Marion Meunier